Menu
Back to Journals » Infection and Drug Resistance » Volume 4
Update on the optimal use of voriconazole for invasive fungal infections
Authors Lat A, Thompson G
Published 3 February 2011 Volume 2011:4 Pages 43—53
DOI https://doi.org/10.2147/IDR.S12714
Review by Single anonymous peer review
Peer reviewer comments 1
Asma Lat1 George R Thompson III2
1Department of Pharmacy, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA; 2Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, and the Department of Medicine, Division of Infectious Diseases, University of California-Davis, Sacramento, CA, USA
Abstract: Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug–drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.
Keywords: therapeutic drug monitoring, aspergillosis, candidiasis, voriconazole
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.